Allogene Therapeutics (ALLO) Stock Price, News & Analysis

Company Overview

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing “off-the-shelf” allogeneic CAR T-cell therapies for the treatment of cancer. Unlike autologous CAR T treatments, which are manufactured from an individual patient’s own cells, Allogene’s therapies are designed to use T cells collected from healthy donors, potentially supporting more standardized manufacturing and broader patient access.

The company’s investigational pipeline includes cemacabtagene ansegedleucel (cema-cel, formerly ALLO-501A), an anti-CD19 CAR T-cell therapy being evaluated in B-cell malignancies, and ALLO-715, an anti-BCMA CAR T-cell therapy being studied for multiple myeloma. Allogene is also developing additional cell therapies targeting blood cancers and solid tumors. These products remain investigational and have not been approved for commercial use.

Allogene was founded in 2018 by former leaders of Kite Pharma and is headquartered in South San Francisco, California. The company’s programs are evaluated through clinical development activities and collaborations involving research and medical institutions in the United States and other regions. David Chang, M.D., Ph.D., is the company’s co-founder, president and chief executive officer.

Key Stats

• Today's Range: $1.77 to $1.84
• 50-Day Range: $1.66 to $2.23
• 52-Week Range: $1.04 to $4.46
• Volume: 7.74 million shs
• Average Volume: 4.81 million shs
• Market Capitalization: $614.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.30
• Consensus Rating: Moderate Buy

Allogene Therapeutics Stock Analysis - MarketRank™

Allogene Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 683rd out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Allogene Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 1 strong buy rating, 8 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Allogene Therapeutics has a consensus price target of $8.30, representing about 366.3% upside from its current price of $1.78.

Amount of Analyst Coverage

Allogene Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Allogene Therapeutics are expected to decrease in the coming year, from ($0.59) to ($0.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Allogene Therapeutics is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Allogene Therapeutics is -2.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Allogene Therapeutics has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.71% of the float of Allogene Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Allogene Therapeutics has a short interest ratio ("days to cover") of 12.15, which indicates bearish sentiment.

Change versus previous month

Short interest in Allogene Therapeutics has recently increased by 0.29%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Allogene Therapeutics does not currently pay a dividend.

Dividend Growth

Allogene Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.55

News Sentiment

Allogene Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Allogene Therapeutics this week, compared to 4 articles on an average week.

Search Interest

15 people have searched for ALLO on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Allogene Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Allogene Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $62,958.00 in company stock.

Percentage Held by Insiders

13.20% of the stock of Allogene Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

83.63% of the stock of Allogene Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/14/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ALLO
• CIK: 1737287
• Web: www.allogene.com
• Phone: (650) 457-2700
• Fax: N/A
• Employees: 152
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Allogene Therapeutics: $8.30
• High Price Target: $14.00
• Low Price Target: $3.85
• Potential Upside/Downside: +366.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.69
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.67)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$190.89 million
• Net Margins: N/A
• Pretax Margin: -3,710.63%
• Return on Equity: -50.04%
• Return on Assets: -36.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.72
• Quick Ratio: 10.72

Sales & Book Value

• Annual Sales: $20 thousand
• Price / Sales: 30,748.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.30 per share
• Price / Book: 1.37

Miscellaneous

• Outstanding Shares: 345,490,000
• Free Float: 299,886,000
• Market Cap: $614.97 million
• Optionable: Optionable
• Beta: 0.47